Department of Pharmacy, Hôpital Henri Mondor, AP-HP Créteil, F-94000, France; Department of Pharmacy, Centre Intercommunal de Créteil Créteil, F-94000, France.
Department of Medical Oncology, Strasbourg Europe Institute of Oncology Strasbourg, F-67033, France.
Eur J Cancer. 2021 Sep;155:145-154. doi: 10.1016/j.ejca.2021.06.051. Epub 2021 Aug 7.
Human microbiota plays a key role in preserving homeostasis; therefore, alteration in its composition is associated with susceptibility to various diseases. Recent findings suggest that gut microbiota may influence response to cancer treatment, especially immune checkpoint blockers (ICBs). The development of ICBs has changed outcomes of patients with cancer and has allowed sustained recovery. Unfortunately, some patients do not respond to ICBs, and microbiota may be a promising new biomarker to identify patients who will have benefit from ICBs. This review presents relationship between microbiome composition or microbiota-derived metabolites and response to ICBs or immune-related adverse events. Furthermore, we will present different strategies to modulate microbiota composition in patients to enhance ICB efficacy or dampen their toxicities which could lead to the emergence of interesting complementary treatments.
人类微生物群在维持体内平衡方面起着关键作用；因此，其组成的改变与易患各种疾病有关。最近的研究结果表明，肠道微生物群可能会影响癌症治疗的反应，特别是免疫检查点抑制剂（ICB）。ICB 的发展改变了癌症患者的预后，并使他们能够持续康复。不幸的是，有些患者对 ICB 没有反应，而微生物群可能是一个有前途的新生物标志物，可以识别出从 ICB 中获益的患者。这篇综述介绍了微生物组组成或微生物衍生代谢物与对 ICB 或免疫相关不良反应的反应之间的关系。此外，我们将介绍不同的策略来调节患者的微生物群组成，以提高 ICB 的疗效或减轻其毒性，这可能会导致出现有趣的互补治疗方法。
